[ad_1] MUNICH: Roche's entrectinib-based cancer pill has been shown to reduce tumors in 57% of patients in a uniquely identifiable group by genetic profile, Swiss drug maker challenging Bayer's alliance with Loxo …
Read More »Roche takes Loxo and Bayer in the cancer class defined by the gene
[ad_1] MUNICH (Reuters) – Roche's entrectinib-based cancer pill has been shown to reduce tumors in 57% of patients in a group that can only be identified by genetic profile, with the Swiss …
Read More »